Third Rock Ventures’ Love Story With Cancer Immunotherapy Results In The Founding Of Jounce Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
The venture firm has pledged $47 million in funding to start-up Jounce Therapeutics to discover and develop biologic drugs for the treatment of cancer.